EE409 Cost Effectiveness of Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.655
https://www.valueinhealthjournal.com/article/S1098-3015(22)02859-5/fulltext
Title :
EE409 Cost Effectiveness of Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02859-5&doi=10.1016/j.jval.2022.09.655
First page :
Section Title :
Open access? :
No
Section Order :
10194